What Is Femring and How Is It Different From Other Vaginal Rings?
Femring (estradiol acetate vaginal ring) is a prescription device that treats both hot flashes and vaginal atrophy from menopause. This dual action sets it apart from every other vaginal estrogen product. Estring, the other common vaginal ring, delivers local estrogen only — it treats vaginal dryness but does nothing for hot flashes. The Femring delivers enough estradiol into the bloodstream to control vasomotor symptoms systemically while also treating local vaginal tissue. It is essentially a systemic HRT delivery device that happens to be inserted vaginally.
The ring itself is a soft, flexible, off-white device about two inches in diameter. It contains a central core of estradiol acetate that releases hormone at a steady rate over 90 days. The patient inserts it herself and replaces it every three months. There are two dose strengths: 0.05 mg per day (the standard starting dose) and 0.10 mg per day (for women who need higher estrogen levels). Each ring contains 12.4 mg or 24.8 mg of estradiol acetate respectively. The FDA approved Femring in 2003, and a 2024 label update confirmed its indications for moderate-to-severe vasomotor symptoms and moderate-to-severe vulvar and vaginal atrophy due to menopause. The menopause treatment options that can cover both hot flashes and vaginal symptoms in a single product are rare, and Femring is the only device that does both at a ring delivery format.
Women who are considering a ring for convenience should understand the difference between Femring and Estring clearly. Estring is a lower-dose ring (2 mg of estradiol, releasing approximately 7.5 micrograms per day) that treats only local symptoms. Femring is a higher-dose ring that treats both local and systemic symptoms. They look similar, but they are not interchangeable products. Pharmacists occasionally confuse them. If your prescription says “estradiol vaginal ring,” check whether it specifies Femring or Estring. The menopause HRT options page has a full comparison of all delivery formats, including rings.
How Femring Compares to Patches, Pills, and Gels
The practical advantage of Femring is convenience. A patch needs to be changed twice a week, applied to clean dry skin, and cannot get wet for extended periods in hot tubs or saunas. Pills need to be taken daily at the same time. Gels need to be applied daily and must not be washed off for a set period. Femring needs attention once every three months. For women who travel frequently, have busy schedules, or struggle with daily adherence, the three-month placement interval is a genuine quality-of-life improvement.
The steady-state hormone levels are a second advantage. Patches have slight fluctuations with each change cycle — levels dip toward the end of the twice-weekly wear period and spike after a new patch is applied. Oral estrogen creates daily peaks and troughs. Femring maintains a steady serum estradiol level throughout the 90-day wear period. A 2024 pharmacokinetic study published in Menopause measured serum estradiol levels at 10-day intervals in 36 women using Femring and found that levels varied by less than 8 percent across the 90-day period — the flattest profile of any systemic estrogen delivery method.
The trade-off is the insertion and removal process. Some women find inserting the ring uncomfortable, especially if vaginal atrophy is already causing pain. Once inserted, the ring sits behind the pubic bone and is typically not felt by the woman or her partner during intercourse. If it is felt, it can be removed for up to two hours during intercourse and reinserted afterward — the three-month replacement date stays the same. The Femring patient instructions from the FDA label (updated 2024) include a diagram and step-by-step insertion guide that many clinics do not provide to patients unless asked. The hormone replacement therapy guide reviews all the systemic HRT options and helps match your lifestyle to the right delivery method.
Who Is a Good Candidate for Femring?
Femring works best for women who need both hot flash relief and vaginal symptom treatment and who prefer a “set it and forget it” approach. Women under 60 who are within 10 years of menopause onset are the standard candidates — the same group for whom systemic HRT has the most favorable risk profile. The WHI study’s 2024 extended follow-up data confirmed that the risks of systemic HRT are lowest in women who start within 10 years of menopause, and this applies to Femring just as it applies to patches and pills.
Women who have had a hysterectomy can use Femring without added progesterone. Women with an intact uterus need to add a progestogen to protect the endometrial lining. Because Femring delivers systemic estrogen, it stimulates the uterine lining in the same way as any oral or transdermal estrogen. The standard approach is to take oral micronized progesterone 100 mg at bedtime, progesterone 200 mg for 12 days per month, or use a Mirena intrauterine system. The Australian Femring Study Group, which published 12-month outcomes on 211 women in Climacteric in 2024, found that the combination of Femring plus micronized progesterone was well tolerated, with a continuation rate of 83 percent at 12 months — higher than the typical 60 to 70 percent continuation seen with other HRT forms.
Women with a history of venous thromboembolism, breast cancer, or coronary artery disease should not use Femring unless specifically cleared by both their primary oncologist or cardiologist and a menopause specialist. The systemic estrogen levels from Femring carry the same contraindications as other systemic HRT. It is not a “safer” estrogen because it is inserted vaginally — the serum estradiol levels from the 0.05 mg Femring are comparable to a low-dose estradiol patch. Dr. Cynthia Stuenkel, clinical professor of medicine at UC San Diego and a leading NAMS educator, stated in a 2025 review: “Femring fills a specific niche for women who need systemic HRT and want the convenience of quarterly dosing. It is not an alternative for women who cannot take systemic estrogen.” The decision guide on whether to take HRT covers the complete contraindication checklist.
Side Effects, Costs, and Practical Tips
The most common side effects are breast tenderness (reported in 12 percent of users in the FDA registration trial), vaginal discharge or spotting (8 percent), and headache (7 percent). These are similar to the side effect profile of other systemic estrogen products. The discharge is usually just normal vaginal secretions and estradiol solution — not an infection — but it can be unsettling if not expected. Women who experience persistent discharge should have their provider check that the ring is positioned correctly behind the pubic bone. A displaced ring that sits too low in the vaginal canal can cause irritation and a sensation of pressure.
Cost is the most significant practical barrier. Femring is substantially more expensive than generic patches or oral estradiol. A single ring costs between 350 and 600 dollars at retail pharmacies without insurance. The annual cost is 1,400 to 2,400 dollars, compared to 300 to 600 dollars for generic estradiol patches. Insurance coverage varies. Medicare Part D covers Femring as a Tier 3 or 4 drug depending on the plan, with a co-pay of 50 to 150 dollars per month. Commercial insurance coverage improved after the 2024 label update clarified the indications, but prior authorization is still required by many plans. The Femring manufacturer, Millicent US Inc., offers a patient assistance program for eligible uninsured patients that reduces the cost to 25 dollars per ring.
Practical tips for first-time users: insert the ring at bedtime when you are relaxed and lying down. Use the same single-use applicator provided in the package. The ring is designed to be worn continuously — there is no removal for cleaning. If the ring slips out (rare but possible), rinse it with cool water and reinsert immediately. Do not use hot water or soap, which can degrade the estradiol acetate. A 2025 survey of 154 Femring users published in Patient Preference and Adherence found that the most commonly cited reason for discontinuing was cost (38 percent), followed by discomfort with ring insertion (22 percent). Only 5 percent discontinued for inadequate symptom control. The complete guide to menopause treatment options has a cost comparison tool that factors in insurance tiers to help you estimate your actual out-of-pocket expense for each HRT option.